Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 38 Melanoma 36 Carcinoma, Non-Small-Cell Lung 16 Colorectal Neoplasms 10 Pancreatic Neoplasms 5 Neoplasm Metastasis 4 Glioma 4 Triple Negative Breast Neoplasms 3 Skin Neoplasms 3 Multiple Myeloma 3 Lung Neoplasms 3 Biliary Tract Neoplasms 3 Thyroid Neoplasms 2 Rectal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurofibroma, Plexiform 2 Neurocytoma 2 Neuroblastoma 2 Leukemia, Myeloid, Acute 2 Histiocytosis, Langerhans-Cell 2 Glioblastoma 2 Ganglioneuroma 2 Ganglioglioma 2 Colonic Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Advanced Solid Tumors 2 Adenocarcinoma of Lung 2 Uveal Melanoma 1

Interventions

Dexamethasone 64 Cyclophosphamide 35 pomalidomide 34 Lenalidomide 34 Rituximab 31 Bortezomib 30 venetoclax 28 fludarabine 27 Gemcitabine 21 carfilzomib 20 Paclitaxel 19 pembrolizumab 17 daratumumab 17 Cisplatin 16 Carboplatin 15 Calcium Dobesilate 14 Azacitidine 14 ibrutinib 12 Docetaxel 12 Cytarabine 12 obinutuzumab 11 Nivolumab 11 durvalumab 10 Injections 10 Doxorubicin 10 Bevacizumab 10 selinexor 9 cemiplimab 9 blinatumomab 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × trametinib × Clear all

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡